2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings. SAN...
From Vietnam National Brand to Regional Giant: SUNHOUSE Secures Second Consecutive APEA Corporate Excellence Award
HANOI, Vietnam, Oct. 26, 2026 /PRNewswire/ -- At the Asia Pacific Enterprise Awards (APEA) 2026, SUNHOUSE was once again honored with the Asia Corporate Excellence Award. Marking its second consecutive victory, SUNHOUSE stands as the sole...
26th Shanghai Fair Returns to Kuala Lumpur to Strengthen Trade and Cultural Ties
KUALA LUMPUR, Malaysia, Oct. 26, 2026 /PRNewswire/ -- The 26th Shanghai Fair Trade Show – Malaysia, organized by RCG International Convention & Exhibition Co. Limited, will take place on 16–17 November 2026 at the Malaysia International Trade...
uSMART and PIVOT Fintech Introduce GlobalSave Portfolios Balanced Strategy on FollowSmart
SINGAPORE, Oct. 26, 2026 /PRNewswire/ -- uSMART Securities (Singapore) Pte. Ltd. ("uSMART") has announced the addition of the PIVOT- GlobalSave Portfolios Balanced Strategy to its FollowSmart platform. Managed by PIVOT Fintech Pte. Ltd. ("PIVOT"),...
RIMAN Connects Global Direct Selling Leaders with K-Beauty Innovation Through WFDSA World Congress and Jeju Experience Tour
RIMAN participated as a Platinum Sponsor of the 18th WFDSA World Congress, highlighting its proprietary ingredients and R&D capabilities The company hosted 24 direct selling industry representatives from nine countries for an exclusive brand...
DiDi Shareholders Overwhelmingly Back Hong Kong Relisting; Want Independent Director, Open Earnings Calls, and First Shareholder Meeting in Four Years, Survey Finds
A Heng Ren Partners survey this month finds at least 99.3% support on five key shareholder issues to boost shareholder value; shareholders want DiDi's board and management to respond with concrete action BOSTON, Oct. 26, 2026 /PRNewswire/ -- Heng...
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). The 2-year OS rate was 54.1% vs 37.2%, an...
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001 ), and median PFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI 5.5-7.4) in the two...